Projects
The beta-cell and the immune system in type 1 diabetes: partners in crime - developing new therapies in type 1 diabetes through better understanding of beta-cell behaviour and use of novel immunomodulators. KU Leuven
The beta-cell and the immune system in type 1 diabetes: partners in crime - developing new therapies in type 1 diabetes through better understanding of beta-cell behaviour and use of novel immunomodulators. KU Leuven
Neutrophils and post-translationally modified beta-cell proteins: a driving force behind type 1 diabetes? KU Leuven
Type 1 diabetes (T1D) is a chronic autoimmune disease characterized by the selective destruction of the pancreatic insulin-producing beta cells by infiltrating immune cells, leading to an absolute insulin deficiency. The prevalence of T1D is increasing worldwide and the concern regarding the number of new T1D cases relates in part to the development of chronic complications, either microvascular (i.e., retinopathy, neuropathy, and ...
Relation between residual beta cell function and glycemic variability in (pre) type 1 diabetes Ghent University
Type 1 diabetes develops when 60 to 90% of insulin-producing beta cellsahve been destroyed. This cell loss leads to greater variability of
blood glucose levels both before and after diagnosis. This variability is predictive of progression to clinical onset of diabetes in risk groups and of
frequenc of hypoglycemic events in patients. Novel beta cell therapy trials aim to prevent or cure diabetes by trying to preserve or restore ...
Identifying phenotypes concerning emotion regulation and emotional eating behaviour in people living with obesity, type 1 diabetes, and both. KU Leuven
Closed-loop insulin delivery in pregnant women with type 1 diabetes (the CRISTAL study) KU Leuven
Type 1 diabetes (T1DM) during pregnancy is associated with increased risk of maternal and neonatal complications such as pre-eclampsia, preterm delivery, caesarean sections, congenital malformations and perinatal mortality. Even with increasing use of new continuous glucose monitoring (CGM) and continuous subcutaneous insulin infusion (CSII, insulin pumps) technologies, pregnant women with T1DM continue to spend on average 8 hours/day ...
Boosting beta-cell function for treatment of type 1 diabetes KU Leuven
In type 1 diabetic (T1D) patients the pancreatic insulin-producing beta cells are selective destroyed by the immune system, leading to an impaired glucose metabolism. The steep increase in the incidence of this chronic autoimmune pathology especially in young children in the last decades raises serious concerns. To date, insulin therapy is considered the gold standard for the treatment of T1D. Nevertheless, limitations persist, such as the ...
Assessing the relevance of a target organ specific microRNA signature in type 1 diabetes KU Leuven
Type 1 diabetes (T1D) is an autoimmune disease that results from T cell-mediated destruction due to a breach in immune tolerance toward the insulin-producing β-cells, leading to an absolute insulin deficiency. T1D clinical presentation does not occur until 80–90% of the β-cells have been destroyed, and there is a marked gap between the onset of autoimmunity and the onset of disease. Therefore, new biomarkers are urgently needed in order to ...
Dialogue between the B-cell and macrophage as starting point for autoimmune type 1 diabetes KU Leuven
Type 1 diabetes (T1D) is an autoimmune disease, whereby insulin producing beta cells are destroyed mainly by T cells, but aspecific inflammation may also play a role in triggering or expanding this process. Our lab has demonstrated that monocytes from T1D patients and macrophages from non obese diabetic (NOD) mice exhibit a hyperinflammatory status and promote the self-reactive T cell stimulatory capacity. Moreover, before beta-cells die ...